Lyra Therapeutics（納斯達克股票代碼：LYRA）報告的季度每股虧損爲$(1.43)，低於分析師一致預期的$(1.38)，相差3.62%。與去年同期每股虧損$(1.26)相比，下降了13.49%。公司報告的季度銷售額爲$1.534百萬，超過分析師一致預期的$1.524百萬，相差0.69%。與去年同期銷售額$1.558百萬相比，下降了1.54%。

以上內容來自Benzinga Earnings專欄，原文如下：

Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of $(1.38) by 3.62 percent. This is a 13.49 percent decrease over losses of $(1.26) per share from the same period last year. The company reported quarterly sales of $1.534 million which beat the analyst consensus estimate of $1.524 million by 0.69 percent. This is a 1.54 percent decrease over sales of $1.558 million the same period last year.